论文部分内容阅读
目的:观察拉米夫定联合阿德福韦酯与单用恩替卡韦治疗失代偿期乙型肝炎肝硬化疗效。方法:将42例失代偿期乙型肝炎肝硬化患者随机分成两组,22例给予拉米夫定与阿德福韦酯治疗为联合组,20例给予恩替卡韦治疗为单用组,观察两组患者实验室生化指标:HBeAg,HBV-DNA参数变化和Child-Pugh评分分级变化等。结果:两组患者生化指标均有明显改善,联合组患者HBeAg阴转率、HBeAg血清转换率和HBV-DNA阴转率分别为45.45%,27.3%,80%,单用组分别为40%,20%,88.9%,两组比较无统计学意义(P>0.05)。结论:从药物治疗经济学考虑,采用拉米夫定与阿德福韦酯联合用药比单用恩替卡韦治疗,价廉,患者更易接受。
Objective: To observe the curative effect of lamivudine combined with adefovir dipivoxil and entecavir alone on decompensated hepatitis B cirrhosis. Methods: Forty-two patients with decompensated hepatitis B cirrhosis were randomly divided into two groups. Twenty-two patients were treated with lamivudine and adefovir dipivoxil, and 20 patients were treated with entecavir alone. Group of patients with laboratory biochemical indicators: HBeAg, HBV-DNA parameters and Child-Pugh score grading changes. Results: The biochemical indexes in both groups were significantly improved. The HBeAg negative rate, HBeAg seroconversion rate and HBV DNA negative rate were 45.45%, 27.3%, 80% in the combined group and 40% in the single group respectively. 20% and 88.9%, respectively. There was no significant difference between the two groups (P> 0.05). CONCLUSIONS: From the perspective of medical treatment economics, the combination of lamivudine and adefovir dipivoxil is more affordable and easier for patients than entecavir alone.